Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
World wide rights of A-273 ? Id rather we go alone as long as possible
How about standard of care AS placebo for ph2/3 to silence critics once and for all. After 3 months, switch to a2-73 as compassionate use and watch what our drug will do compared to soc .
Happy new year
http://m.hawaiinewsnow.com/hawaiinewsnow/pm_/contentdetail.htm?contentguid=od:QuUNUyxE
Halfway down FDA wanted analysis of result so fare em though trial wasn't done . 82 of 121 was eligible for the result readout.
Sounds like Anavex one day soon.
Too funny. Now that Anavex has something that has different results than what BP gets, now the mouse is the problem? Like it or not, they have what BP wishes they could get their hands on.
I'm thinking this extended ph2a/b will help gather the needed data to stop ph2/3 early if the endpoints are met as the drug is proven safe. I thought 2016 would of been an exciting year for Anavex, but I was wrong as the powers that be don't want this company valued too much. 2017 or 18 or 19, doesn't matter. I'm not letting go of my shares.
If it happens to drop to 3.50ish, That's when I'll be adding. Hopefully it doesn't though.
Mele Kalikimaka and bad juju to AF
When did Jan 2017 options start having 10 12.50 and 15 call and puts? Every other time it only went up to 7.50
Shorts could care less about what the company is about. Emotions are a scary thing to have when investing. I understand what you are saying though. Besides I prefer the quote from princess bride in that scenario.
"My name is Inigo Montoya. You killed my father. Prepare to die"
Like it or not, a-273 will go through a ph2/3 in at least Australia. IMO, Australia will have first approval of the drug as they understand how it helps their health system and more importantly their citizens. BP trying their best to keep this company obscure and confuse people with the fud. It's a game of chess and Missling is,so far, winning.
Dilute? Pfttt!!!!
Scam? Smart people in their respective field wouldn't dare put the respect they have on a scam.
Stupid? Lol if all else fails resort to name calling.
Thanks for your dd, but mine indicates something totally different. AF is the scum at the edge of a dirty tub. Paid by the highest payer. Good luck with your shorting and hope you learn your lesson soon.
That's a pretty good assumption being that 5 week results of the original 32 were already better than soc. So from 52-57 weeks there should have already been a noticeable difference in scores.
If he executes his plan not forgetting to cross the t's and dotting the i's, it will be peanuts compared to how much value he brought the Anavex.
Imagine how many ceos would be out of cash and desperate after being attacked again and again by jealous types.
Yep, and thankfully we are in good hands with our CEO.
Announcing we are good for at least 2 years should put a little worry on the same ones that are trying to bury us, hoping that we run out of money and have to close up shop. Hoping that we dilute so they can continue with their I told you so's. If only the Warren Buffett's of the world knew about us we would be were we truly belong. Its ok though because some of us retails know that this type of stock potential comes along once every decade or so.
Same could be said about Axovant. Employees may be a little higher.
They got the patent rights for their molecule from one glaxosmithkline who deemed it "sold to the only bidder", and by the way, before you purchase it, please know that it failed a ph3 already.
The only people that will be rich is the hedge funds that are in this gimmick. Fleecing the investors along the way.
IF one has the patience to hold. Seems like a few of us expect multi dollar days after data release. Slowly but surely we will get there, till then, don't let them take your shares on the cheap.
You were correct again. $5 expiring worthless. ????
Nope, I believe in Anavex approach vs what everyone else is still trying. Perfect example for the meaning of insanity.
The same reasons why Anavex did with 25 patients what BP could never do with 1,2, or even 3 thousand patients. You really think it's a coincidence why we are down here in the low 4's with all the great data that was released over the year? We are being held down by big $$.
They probably would convince themselves that it's a paid actor. BP hear them footsteps of little Annie getting louder.
Can you post a screenshot of the email to confirm what you quoted.
Are we not allowed to get an outstanding stock anymore like how JGB used to get for us?
And according to the shorts, it is no better than placebo. Desperate times calls for desperate measures. IMO, they can't do this for much longer before they get trapped and squeezed. Can't wait for THAT birthday present.
AF tweeted that Anavex paid Biogen for testing their drug when Anavex released the PR about the moa.
You saw that he took a stab at AF too by mentioning that BIIB is not a vendor that does tests for payment?
Yes he did say that. So my take away is he knows where he will get the money from and just can't say yet. 16 Million is good for 2 years and starting p2 trials for PK and Rett, and p2/3 for AD. He's getting money and it won't be from dilution. He said that the drug has already been manufactured for the Rett trial so I'm betting it starts soon. 3 months later, we find out if a2-73 works for Rett and off the p2/3 if it does.
Long story short, I see no reason to sell after this conference call.
Xena,
Remembering you talked about Takeda being a possible partner for the Asian market, Steffen Thomas used to work for Takeda. Also, before working there, he worked for a Company that Takeda bought out for $10B. Not saying that Anavex will get bought, just that there IS a connection.
Another sticky worthy post
There is a poison pill, dig deeper and you'll find it. There's a lot of authorized shares than can be released in such a scenario.
I hope the Dr. laughs at all offers of a buy out and offers partnership or nothing. Why sell out to BP when you have the most promising drug to help multiple cns diseases. I don't care about fast money, I'm in it for the long haul. 10-15 years could turn a measly $1000 into 6-7 digits if we have THE drug. Still a ways away and could lose everything too.
This looks like a shout out to Anavex and their trial design, no?
However, he said changes are needed in the design of clinical trials, especially for drugs intended to stop disease progression rather than treat symptoms. “Disease-modifying drugs act slowly and it’s hard to measure their effect, so selecting an optimal dose in a manageable sized trial is impossible,” he said. Consequently, sponsors have moved into large, costly, phase 3 (confirmatory) trials without knowing the correct dose. “I think that accounts for an enormous amount of failure over the last twenty years,” said Aisen.
Adding to that:
Axovant - 5HT6 receptor
Anavex - Sigma-1 receptor
When I re-read my comments and realize I don't have a clue what direction I'm going, I hit cancel post.
Its responses from 16 different patients. 2 patients had 2 comments.
Yes, but I'm more sympathetic for the patients. Glad to see that they finally put those types of comments in a presentation.
Slide 30 is a beautiful thing.
Documented patient comments
I was monitoring the site for changes too. Guess I didn't have enough coffee this am. Thanks
Yes and everything else is just noise to try and get you to sell your shares
Until they release bad data or prs, I don't know about you, but its been a long for me since I found out about this company over a year and a half ago.
That's what I was thinking this morning when I read that pr. LLY tryin to low ball US!!
Large being a number according to whom? Our own CEO said a p3 will have about 300 participants. Is 300 large enough for a p3 or are we so used to having thousands of participants that it has to have thousands before the statistics have any truth. After all, the we are getting guidance from the FDA.